Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment (Q38725320)

5 September 2017

1 reference

title

Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment (English)

1 reference

5 September 2017

1 reference

Jia-Sin Yang

1

1 reference

5 September 2017

Chiao-Wen Lin

series ordinal

2

1 reference

5 September 2017

Shih-Chi Su

series ordinal

3

1 reference

5 September 2017

Shun-Fa Yang

series ordinal

4

1 reference

5 September 2017

language of work or name

English

0 references

publication date

11 January 2016

1 reference

Expert Opinion on Drug Metabolism & Toxicology

5 September 2017

published in

1 reference

5 September 2017

volume

12

1 reference

5 September 2017

issue

2

1 reference

5 September 2017

page(s)

191-200

1 reference

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

21 January 2018

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Current mechanistic insights into the roles of matrix metalloproteinases in tumour invasion and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Matrix metalloproteinases and their tissue inhibitors in gastric cancer as molecular markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Matrix metalloproteinase-2 as a target for head and neck cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

High level of plasma matrix metalloproteinase-11 is associated with clinicopathological characteristics in patients with oral squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Phosphonate Emerging Zinc Binding Group in Matrix Metalloproteinase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

New strategies for targeting matrix metalloproteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Matrix metalloproteinase inhibitors: a patent review (2011 - 2013).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

The C-terminal region of membrane type matrix metalloproteinase is a functional transmembrane domain required for pro-gelatinase A activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Control of matrix metalloproteinase catalytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Matrix metalloproteinase 10 promotion of collagenolysis via procollagenase activation: implications for cartilage degradation in arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Beta-hematin interaction with the hemopexin domain of gelatinase B/MMP-9 provokes autocatalytic processing of the propeptide, thereby priming activation by MMP-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Catalytic domain architecture of metzincin metalloproteases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Membrane type-matrix metalloproteinases (MT-MMP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Matrix remodeling by MMPs during wound repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Matrix metalloproteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Matrix metalloproteinases and the regulation of tissue remodelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Matrix metalloproteinases and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Moving targets: Emerging roles for MMPs in cancer progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Series "matrix metalloproteinases in lung health and disease": Biological role of matrix metalloproteinases: a critical balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Tissue inhibitors of metalloproteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Molecular mechanisms of tissue inhibitor of metalloproteinase 2 in the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Metalloproteinase binding proteins: WO2009097397.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Metalloproteinase inhibitors: biological actions and therapeutic opportunities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Matrix metalloproteinases: biologic activity and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

1.8‐Å Crystal Structure of the Catalytic Domain of Human Neutrophil Collagenase (Matrix Metalloproteinase‐8) Complexed with a Peptidomimetic Hydroxamate Primed‐Side Inhibitor with a Distinct Selectivity Profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Chemically modified tetracyclines as inhibitors of matrix metalloproteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Matrix Metalloproteinase Inhibition Attenuates Human Pancreatic Cancer Growthin Vitroand Decreases Mortality and Tumorigenesisin Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Reduced angiogenesis in peritoneal dissemination of gastric cancer through gelatinase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Development of matrix metalloproteinase inhibitors in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Promising new developments in cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Inhibition of proliferation and induction of apoptosis by doxycycline in cultured human osteosarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Transforming growth factor beta1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

MMP inhibition in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Effects of doxycycline on human prostate cancer cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

MMP inhibition and downregulation by bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Matrix metalloproteases in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Role of matrix metalloproteinase-9 dimers in cell migration: design of inhibitory peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Structural and functional bases for allosteric control of MMP activities: can it pave the path for selective inhibition?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1131820

10.1517/17425255.2016.1131820

21 January 2018

Identifiers

DOI

1 reference

5 September 2017

1 reference